PDS Biotechnology Corp (PDSB) – Phase 2 HPV Trial With PDS0101 Reaches Enrollment Milestone

0 min read

Wednesday, March 16, 2022

PDS Biotechnology Corp (PDSB)
Phase 2 HPV Trial With PDS0101 Reaches Enrollment Milestone

PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is primarily engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.

Robert LeBoyer, Vice President, Research Analyst, Life Sciences, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Phase 2 Enrollment Is On Schedule.  PDS Biotechnology has announced that the National Cancer Institute (NCI) Phase 2 trial testing PDS0101 in a triple-therapy regimen has reached the target patient enrollment in one of its two treatment arms. This trial is testing PDS0101 in combination with two immune modulating drugs in HPV-associated cancers.

    PDS0101 Is Being Tested With Immune Modulators To Improve Response.  PDS0101 (Versamune-HPV16) uses the PDS Versamune technology with the HPV-16 antigen. It was designed to activate immunological pathways, stimulating an immune response against cancer cells with the human papilloma virus antigen. The trial is testing PDS0101 with two other immune modulating drugs (the bifunctional checkpoint …

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 


Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy
© 2018-2023 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.